Innocan secures Mexican patent for topical pain-relief technology
Pharmaceutical biotechnology company Innocan Pharma (CSE:INNO) announced a significant milestone in its global intellectual property strategy
The Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for Innocan's patent application covering its proprietary topical pain-relief formulation
The company explained that this newly approved patent protects a unique blend of cannabidiol (CBD) and minerals designed to deliver fast-acting, localized pain relief
Innocan Pharma stock (CSE:INNO) last traded at $0.16
Pharmaceutical biotechnology company Innocan Pharma (CSE:INNO) announced a significant milestone in its global intellectual property strategy.
The Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for Innocan's patent application covering its proprietary topical pain-relief formulation.
In a media statement, the company explained that this newly approved patent protects a unique blend of cannabidiol (CBD) and minerals designed to deliver fast-acting, localized pain relief. Clinical studies have shown that the formulation provides noticeable pain reduction within just 20 minutes of application, underscoring its potential as a next-generation therapeutic solution.
The Mexican patent joins previously granted counterparts in the United States and Ukraine, reinforcing Innocan's expanding global IP portfolio. The company also maintains a growing number of pending applications in key jurisdictions worldwide.
With this latest development, Innocan Pharma is able to strengthen its presence in Latin America, a region with increasing demand for advanced, non-invasive pain relief solutions. The company continues to explore partnerships and commercialization opportunities to bring its products to market.
Innocan Pharma Corp. is active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the company aims to provide non-opioid chronic pain management solutions for both animals and people.
Innocan Pharma stock (CSE:INNO) last traded at $0.16.
Join the discussion: Find out what everybody's saying about this stock on the Innocan Pharma Bullboard investor discussion forum, and check out the rest of Stockhouse's stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 days ago
- Cision Canada
Charlotte's Web Reports Shareholder Meeting Voting Results
LOUISEVILLE, Colo., June 13, 2025 /CNW/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. (" Charlotte ' s Web" or the " Company") is pleased to announce the results from its 2025 annual general meeting of shareholders held on June 12, 2025 via live audio webcast (the " Meeting"). Each of the matters voted upon at the Meeting is discussed in detail in the Company's Proxy Statement dated April 29, 2025, a copy of which is available on the Company's SEDAR profile at and on EDGAR at The total number of votes cast at the Meeting was 58,493,957, representing 36.87% of the total number of votes attached to the outstanding voting shares of the Company. According to the proxies received, the results of the vote for the election of directors were as follows: Detailed results of the matters considered at the Meeting are reported in the Report of Voting Results as filed on the Company's SEDAR+ profile at About Charlotte's Web Holdings, Inc. Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is a botanical wellness innovation company and a market leader in hemp extract wellness that includes Charlotte's Web whole-plant full-spectrum CBD extracts as well as broad-spectrum CBD and cannabinoid isolates. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, THC, terpenes, flavonoids, and other beneficial compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery, immunity), CBN gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams, and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online through the Company's website at
Cision Canada
2 days ago
- Cision Canada
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: The article discusses the therapeutic potential of long-acting synthetic cannabidiol (CBD) in addressing chronic pain—an urgent global health challenge for which safer, more effective treatments are desperately needed. Co-authored by leading pain specialists from institutions such as Johns Hopkins University and NYU School of Medicine, the review highlights that synthetic CBD administered through extended-release formulations could offer a well-tolerated, non-opioid analgesic alternative with the potential to significantly reduce reliance on addictive opioids. Chronic pain affects over 24% of adults in the United States alone, placing a significant burden on patients, healthcare systems, and economies*. Yet, long-term treatment options remain inadequate. NSAIDs pose cumulative toxicity risks, and opioids—while effective—present serious concerns including tolerance, dependency, and overdose risk. Globally, opioid misuse results in over 100,000 deaths annually (DOI: 10.1016/ The U.S. Food and Drug Administration (FDA) has emphasized the critical need for novel, non-addictive pain therapies through its "Guidance for Industry: Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by various animal studies, LPT-CBD produces steady CBD plasma levels for up to four weeks, delivers prolonged pain relief, and is well tolerated, offering a promising alternative to current opioid medication and abuse. Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks a pivotal step toward realizing a first-in-class, non-opioid analgesic therapy tailored for the complexities of chronic pain management. "This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy," said Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine and co-author of the article. "Liposomal synthetic CBD could offer a safe and scalable solution for a variety of painful conditions." "Given the current addiction crisis, there is an immediate need to replace opioids with safer, effective alternatives," noted Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health and co-author of the article. "Long-acting synthetic CBD has real potential to shift the paradigm." Iris Bincovich, Chief Executive Officer of Innocan added:"We are thrilled by this breakthrough publication. Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management." Reference Opioid crisis: addiction, overprescription, and insufficient primary prevention, The Lancet Regional Health – Americas 2023;23: 100557. DOI: 10.1016/ , Eugene Vortsman, Christopher Gharibo, Jo Ann K. LeQuang, Joseph V. Pergolizzi. Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. Cureus Journal of Medical Science. DOI: 10.7759/cureus.81577 About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Winnipeg Free Press
3 days ago
- Winnipeg Free Press
House passes bill to to combat fentanyl trafficking, sending it to Trump's desk
WASHINGTON (AP) — The House overwhelmingly passed bipartisan legislation Thursday that would solidify federal policies cracking down on the synthetic opioid fentanyl and its analogs in a bid by lawmakers to combat the nation's opioid epidemic. The HALT Fentanyl Act makes permanent a 2018 emergency rule that classifies knockoffs of fentanyl as Schedule I controlled substances, which results in harsher sentences for possession of the drug. The bill passed the House 321-104 and now heads to President Donald Trump for his signature. The legislation, which applies to what are known as known as 'fentanyl-related substances,' garnered support from nearly every Republican and many Democrats despite concerns that the bill does not address the root issues at hand and will add to problems in the criminal justice system. Senate Majority Leader John Thune hailed passage of the bill and promised more legislative action to come. 'I don't need to tell anybody about the horrible impact of drug overdoses in this country, many of them caused by fentanyl,' Thune said on the Senate floor. 'In the coming weeks, we'll be taking up legislation to address another aspect of the fight: securing our borders,' a nod to Republicans' tax package, which includes billions of dollars in additional immigration enforcement and border security funding. Proponents of the legislation argue that the bill will make it easier to stop drug traffickers by making the federal emergency rules permanent. Opponents say the framework does little to stem the epidemic and warn it will make it harder to conduct important research. Congress has regularly renewed the emergency rules since 2018, meaning there is no immediate change to federal policy. The bill does not include increased funding for law enforcement to conduct anti-drug trafficking efforts, nor funding for public health efforts meant to reduce fentanyl addiction and deaths. The bill's supporters say that the reclassification will give anti-trafficking efforts clearer standards to operate under as law enforcement combats the trade. Federal, state and local law enforcement have sought to break up the flow of fentanyl into the U.S. by targeting Mexican drug cartels and local gangs. The Trump administration has declared stemming the flow of fentanyl precursors from China a priority in trade talks with Beijing, an effort that follows a spate of initiatives by the Biden administration to reduce the importation of such substances into the U.S. from China and other illegal supply chains. 'A loophole that the cartels have tried to use to drive their illicit fentanyl into our country is by changing one part of the fentanyl chemical structure to create fentanyl analogs,' said GOP Virginia Rep. Morgan Griffith, one of the bill's co-sponsors, during Wednesday's debate on the House floor. 'The cartels did this in an attempt to evade our criminal laws,' said Griffith, who argued that the bill would help prevent further fentanyl deaths and increase the potential for research into the drug and related substances. And lawmakers appealed to the human cost of fentanyl smuggling. 'We must give our law enforcement the tools to combat this problem. This bill does exactly that,' said GOP California Rep. Jay Obernolte, a co-sponsor of the bill. Obernolte recounted the stories of families impacted by fentanyl overdoses in his district and noted that more than 100,000 Americans died of an overdose last year, mostly from fentanyl. The bill 'gives our law enforcement agencies the tools that they need to begin dealing with this problem,' Obernolte said. Democratic New Jersey Rep. Frank Pallone said during debate that he opposed the bill because it uniformly criminalizes fentanyl related substances. Pallone said it will impede potential research into their benefits rather than provide an 'offramp to substances found to have potential medical applications.' Pallone also chided Republicans for saying they aimed to tackle the opioid epidemic while supporting the Trump administration's cuts to federal agencies tasked with research and public health policy. 'This Republican bill would also exacerbate inequities in our criminal justice system because drugs placed on Schedule I include mandatory minimum sentencing,' Pallone said. 'The bill is essentially recycling an incarceration first response to what I consider mainly a public health challenge.' Schedule I drugs are substances considered by the Drug Enforcement Agency to have 'no currently accepted medical use and a high potential for abuse.' Possession of a Schedule I drug is considered a felony and can be prosecuted as drug smuggling. Drugs currently classified as Schedule I include heroin, marijuana and methaqualone. Fentanyl itself is classified as a Schedule II drug, which the DEA designates as having 'a high potential for abuse.' Schedule II substances include cocaine, methamphetamine, oxycodone and Adderall.
